AR and hepatocellular carcinoma: This overlap between AR/AR-SV-suppressed oncogenic pathways in AR-SV(±) HCC and niclosamide’s anti-AR and anti-cancer activity well positions niclosamide as a potential HCC therapeutic that can address this complex signaling.